Please login to the form below

Not currently logged in
Email:
Password:

brigatinib

This page shows the latest brigatinib news and features for those working in and with pharma, biotech and healthcare.

Modest meeting sees only two drugs recommended by CHMP

Modest meeting sees only two drugs recommended by CHMP

Also picking up label extensions were Takeda’s Alunbrug (brigatinib), Boehringer Ingelheim’s Ofev (nintedanib) and Amgen’s Otezla (apremilast).

Latest news

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase ... Company acquisition. Rare diseases, option

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics